Trending Health Vynamic

As competitive and regulatory pressures increase, Life Sciences organizations are tightening their timelines and budgets when bringing products to market. In this environment, it’s become essential to start commercialization planning earlier to ensure a successful launch and hit revenue targets. In this deep dive episode, Jen is joined by Vynamic’s Product Launch Service Leads, Ashley Stanley and Brian Stamm, as well as Managing Director of PROPENSITY4, Chris Savage, to discuss why early planning is so critical and how leaders can incorporate some of these changes into their organizations.  To learn more about Vynamic’s work in Product Launch, visit Vynamic’s Product Launch (%5C) page. To read more on navigating alliance product launches, see Vynamic’s latest insight here (%5C).  PROPENSITY4, part of Inizio Engage, is transforming pharmaceutical commercialization through seamless integration of data, expertise and cutting-edge analytics. See more about what PROPENSITY4 can do for your team at Data and Integrated Insights | Inizio Engage. (%5C)  Podcast Tags: healthcare, life sciences, product launch, healthcare news, life sciences trends, product launch trendsSource Links:* Product launch challenges and how to overcome them (%5C)* Drug launches reflect overall company performance (%5C)* TO SPEND OR NOT TO SPEND: Investing For Launch Success As An Emerging Company (%5C)* Revenue of the worldwide pharmaceutical market from 2001 to 2023 (%5C)* Prices for new US drugs rose 35% in 2023, more than the previous year (%5C)* Next in pharma 2024: Reinventing for returns (%5C)* The Unbearable Cost of Drug Development (%5C)* Understanding the Factors that Impact the Pre-Launch Phase and New Product Launch Excellence in the Pharmaceutical Industry (%5C)* FDA Approves Many New Drugs in 2023 that Will Benefit Patients and Consumers (%5C)Panel – Jen Burke, Ashley Stanley, Chris Savage, Brian StammResearch & Production – Adrea Cope & Everly PetruzzelliRecording & Editing – Mike Liberto, Rachel SkoneckiFor additional discussion, please contact us at TrendingHealth.com (%5C) or share a voicemail at 1-888-VYNAMIC.

In this episode, Mindy, Ryan, and Jen discuss recent newsworthy items, including the FDA approval of Rejoyn, the first prescription digital treatment for major depressive disorder. They also discuss the ongoing drug shortage crisis, as well as changes coming out of the Centers for Medicare & Medicaid Services and the impact those decisions will have over the next year.  Podcast Tags: healthcare, healthcare news, life sciences, health policy, public health, depression, mental health, digital treatment, drugs, pharmaceuticals, shortages, medications, FDA, CMS, Medicare Advantage, breakthrough technology, medical devices Source Links: * FDA clears first digital treatment for depression, but experts caution that research is still early (%5C) * Number of ongoing US drug shortages reaches new high, pharmacist group says (%5C) * FDA commissioner tells lawmakers his agency needs more authority to prevent drug shortages (%5C) * CMS final rule on broker comp, health equity could shake up Medicare Advantage (%5C) * Medicare official says breakthrough device reimbursement rule coming in early summer (%5C)  Panel – Jen Burke, Mindy McGrath, Ryan Hummel Research & Production – Anna Briccetti, Jen Burke Recording & Editing – Mike Liberto, Rachel Skonecki  For additional discussion, please contact us at TrendingHealth.com (%5C) or share a voicemail at 1-888-VYNAMIC.

While the health industry is not always an early adopter of new technologies, the growth of generative artificial intelligence (GenAI) has empowered organizations to start transforming their AI aspirations into actions. In this episode, Mindy and Jen are joined by Vynamic’s Innovation Lead, Michael Hudson, and Responsible AI Lead, Todd Quartiere, to discuss where we see health organizations experimenting with AI and what it will take for them to achieve their long-term AI ambitions.To learn more about implementing AI within your organization, check out our recent insight: Why AI fails or flourishes: The underestimated role of culture (%5C).Podcast Tags: health, healthcare, healthcare news, generative AI, innovation, responsible use, ChatGPTSource Links:* The Unexpected Winners of the ChatGPT Generative AI Revolution (%5C) * Generative AI in healthcare: Emerging use for care (%5C) * US healthcare leadership: How to respond and thrive (%5C) * How Can AI Improve Health Care? (%5C) * Envisioning Healthcare in a Post-COVID-19 World (%5C) * Three-quarters of health professionals project widespread AI adoption (%5C) * 5 Key Healthcare Industry Trends to Watch in 2024 (%5C) * What Do We Mean When We Talk About “AI Democratisation”? (%5C)  Panel – Jen Burke, Michael Hudson, Mindy McGrath, Todd QuartiereResearch & Production – Danielle Lewis, Jen BurkeRecording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com (%5C) or share a voicemail at 1-888-VYNAMIC.

In this Trending News Europe episode, Jack, Jen, and Ollie discuss recent newsworthy items from across Europe, including the impact of and deterrents against “no shows” at medical appointments, the role bacteria play in cancer treatment, and inequalities in the rare disease market, along with the steps being taken to ease these issues.Podcast Tags: healthcare, healthcare news, life sciences, public health, France, medical, bacteria, cancer, immunotherapy, chemotherapy, microbiome, rare disease, Germany, Italy, health disparity  Source Links:* Dutch hospitals use AI to solve no-show patient problems that cost them millions (%5C)  * Cancellations of NHS care are having serious impacts on two-thirds of patients (%5C)  * Would charging patients for missed appointments help fund the NHS? (%5C)  * GP \’no shows\’ cost Norfolk NHS more than 1m in a one month (%5C)  * France planning €5 no-show fees in a bid to improve community healthcare (%5C)  * France divided over ‘no-show tax’ for patients failing medical appointments (%5C)  * Researchers compile detailed catalog of bacteria living in cancer metastases (%5C)  * Boehringer builds out cancer capabilities with $500M deal for bacteria-focused Swiss biotech (%5C)  * The key to young onset bowel cancer may be gut bacteria (%5C)  * The mystery of microbes that live inside tumours (%5C)  * Diversity of Bacteria in Cancer Metastases (%5C)  * It’s the Little Things: A Role for Bacteria in Cancer Treatment (%5C)  * The UK is missing out on EU collaboration to improve treatment for rare diseases (%5C)  * Overcoming the burden of rare diseases in Europe (%5C)  * Stronger together in the fight against rare diseases (%5C)  * Is Europe on track to be the leader in rare diseases? (%5C)  * Right here, right now European public health policies must start giving people living with rare diseases a fair chance (%5C)  * New rare diseases action plan on horizon, Europe at turning point (%5C)  * Europe needs new 360 rare diseases strategy (%5C)   Panel – Jack Young, Jen Burke, Ollie May  Research & Production – Karan Pandya  Recording & Editing – Mike Liberto, Rachel Skonecki   For additional discussion, please contact us at TrendingHealth.com (%5C) or share a voicemail at 1-888-VYNAMIC.

In recent years, we’ve seen an increasing number of Life Sciences companies publicly declare commitments to sustainability efforts as a result of increased pressure from governments, customers, and research. Trending Health UK’s Ollie May sits down with two members of Vynamic’s Sustainability Council, Rosanna Vellacott and Matt O’Dell, to discuss why pharmaceutical organizations should be paying attention to sustainability goals, some innovative practices underway, and what leaders should be considering as they embed more sustainable practices into their organizations. 
Podcast Tags: healthcare, life sciences, sustainability, healthcare news, climate change, climate crisis, emissions, net zero, supply chain 
 
Source Links: 
* Striving for sustainable drug discovery using Green Chemistry 
* Accelerating the transition to net zero in life sciences 
* Process Digital Twin for Pharma 
* Sanofi harnesses Dassault\’s digital twin tech to optimize production at future vaccine plants 
* Strategies for Sustainability in the Global Pharmaceutical Supply Chain 
* Bayer: Improving Sustainability Practices in the Supply Chain 
* Bayer: Commitments in Action Creating a Sustainable Product Supply 
* Making biopharma’s supply chains more environmentally sustainable 
* The pharma companies working towards supply chain sustainability 
* Carbon footprint of the global pharmaceutical industry and relative impact of its major players 
* The Greenhouse Gas Protocol: Technical Report  
* Understanding pharma’s challenges and opportunities in relation to the climate crisis
* Pharmaceutical Company Targets and Strategies to Address Climate Change: Content Analysis of Public Reports from 20 Pharmaceutical Companies 
* Pharma’s path to Net Zero: Targeting Scope 3 emissions 
 
Panel – Oliver May, Rosanna Vellacott, Matt O’Dell 
Research & Production – Adrea Cope, Everly Petruzzelli, Oliver May  
Recording & Editing – Mike Liberto, Rachel Skonecki 
 
For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

In this Trending News US episode, Jen, Mindy, and Ryan discuss recent newsworthy items, including the introduction of rebate credits by CVS to account for more biosimilars entering the market, as well as a recent ruling by a federal appeals court that drugmakers cannot restrict 340B program offerings from community and specialty pharmacies. Finally, we discuss a groundbreaking procedure in which a kidney from a CRISPR gene edited pig was transplanted into a human.Podcast Tags: healthcare, healthcare news, CVS health, PBMs, biosimilars, 340B, pharmacies, hospitals, providers, xenotransplantation, CRISPR, gene editingSource Links:* As Humira biosimilars take over the market, CVS has created a new ploy; the drug “rebate credit” (%5C)* Federal appeals court sides with 340B contract pharmacies (%5C) * American Hospital Association 340B Factsheet (%5C) * Gene edited pig kidney transplanted into a living patient for the first time (%5C)* Kidney Disease Statistics for the United States (%5C) Panel – Jen Burke, Mindy McGrath, Ryan Hummel Research & Production – Anna Briccetti, Jen Burke Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com (%5C) or share a voicemail at 1-888-VYNAMIC.